表紙
市場調查報告書

液態切片研究工具、服務、診斷的全球市場

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

出版商 BCC Research 商品編碼 350412
出版日期 內容資訊 英文 261 Pages
訂單完成後即時交付
價格
液態切片研究工具、服務、診斷的全球市場 Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
出版日期: 2019年03月08日內容資訊: 英文 261 Pages
簡介

全球液態切片 (液態生物檢體) 市場,預計從2018年的24億美元,到2023年擴大到61億美元。市場,預計2018年∼2023年20.8%的年複合成長率(CAGR)成長。

本報告提供全球液態切片研究工具、服務、診斷市場相關調查分析,市場概要,技術的背景,市場趨勢分析與預測,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 摘要

第3章 概要

  • 簡介
  • 調查範圍
  • 液態切片 vs. 傳統活體組織切片
  • 市場
  • 成長促進因素
  • 主要趨勢
  • 產業

第4章 技術的背景

  • 液態切片生物標記
  • 癌症基因學
  • 非侵襲產前檢查
  • 循環腫瘤細胞 (CTC) 技術
  • CTC工作流程
  • 細胞離析技術
  • CTC樣品製作技術
  • CTC下游分析技術
  • 液態切片和傳統活體組織切片的比較
  • 癌症檢驗
  • 產前檢查

第5章 液態切片舉措

第6章 市場明細:各終端用戶

  • 簡介
  • 癌症應用
  • 生殖健康應用
  • 移植診斷應用

第7章 液態切片產業

  • 先進定序設備產業
  • 微滴式數位PCR (DDPCR) 產業
  • 靶向序列捕獲、調整產業
  • 單細胞DNA聚合酵素產業
  • 非侵襲產前檢查產業
  • 胎兒細胞NIPT產業
  • CTC採取、檢測產業
  • 液態切片化驗產業

第8章 產業收購和策略性聯盟

  • 收購
  • 策略性聯盟

第9章 液態切片市場

  • 成長促進因素
  • 液態切片市場:各適應症
  • 液態切片市場:各生物標記類型
  • 液態切片市場:各分析平台
  • 液態切片市場:各分析目的
  • 非侵襲產前檢查市場
  • 癌症市場
  • 移植市場
  • 各地區市場

第10章 專利分析/新開發

  • CTC專利
  • 外吐小體專利
  • 無細胞DNA專利
  • 液態切片、定序相關專利的問題點

第11章 企業簡介

關於BCC Research

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO150C

Report Highlights:

The global liquid biopsy market should reach $6.1 billion by 2023 from $2.4 billion in 2018 at a compound annual growth rate (CAGR) of 20.8% for the period 2018 to 2023.

The global noncancer liquid biopsy market is expected to grow from $1.9 billion in 2018 to $3.7 billion in 2023 at a CAGR of 13.8% for the period 2018 to 2023.

The global cancer liquid biopsy market is expected to grow from $411.7 million in 2018 to $2.4 billion in 2023 at a CAGR of 41.7% for the period 2018 to 2023.

Report Scope:

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents, and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments; droplet digital PCR (polymerase chain reaction); target enrichment; single-cell DNA polymerase; non-invasive prenatal testing (NIPT); fetal-cell NIPT; CTC (circulating tumor cell) capture and detection; and liquid biopsy.

The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics, and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring), and geography (North America, Europe, Asia/Pacific, Rest of World).

Market data covers 2017, 2018 and 2023 (forecasted).

More than 175 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.

Report Includes:

  • 32 data tables and 54 additional tables
  • Industry analysis of the liquid biopsy biomarkers and technologies market
  • Analyses of global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Characterization and quantification of market potential for liquid biopsy diagnostics by application, biomarker type, analysis platform, analysis purpose and geographical region
  • Discussion of several significant large-scale research initiatives that are contributing to liquid biopsy market development
  • Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
  • Coverage of significant patents and their allotments in each category, as well as major industry acquisitions and strategic alliances data
  • Company profiles of major manufacturers and suppliers of liquid biopsy research tools, services and diagnostics, including Agilent Technologies Inc., Cygnus Biosciences, Illumina Inc., Oxford Nanopore, Qiagen, Quantum Biosystems, Roche and Thermo Fisher Scientific

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary

Chapter 3: Overview

  • Introduction

Report Scope

  • Liquid Biopsy Versus Traditional Biopsy
  • Markets
  • Forces Driving Growth
  • Key Trends
  • Industry

Chapter 4: Technology Background

  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Non-Invasive Prenatal Testing
  • Circulating Tumor Cell Technologies
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
  • Cancer Testing
  • Prenatal Testing

Chapter 5: Liquid Biopsy Initiatives

  • Blood Profiling Atlas
  • Cancer-ID
  • CTC Trap Consortium
  • Early Cancer Detection Consortium
  • EpiFemCare
  • Human Cell Atlas
  • Immunomonitor Consortium
  • Integration of Imaging and Fluid-based Tumor Monitoring in Cancer Therapy Program
  • Liquid Biopsies and Imaging for Improved Cancer Care
  • Next-Generation Single-Cell Analysis Program
  • Population Sequencing Projects
  • Precancer Atlas
  • Precision Medicine Initiative
  • Single-Cell Proteomics and Lipidomics Project
  • TopMed
  • Worldwide Innovative Networking (WIN) Consortium
  • Single-Cell Research
    • Cambridge Single-Cell Analysis Core Facility
    • Harvard Medical School Single-Cell Core
    • Mayo Medical Genome Facility
    • National Center for Single-Cell Biology
    • Single-Cell Analysis Core
    • UC San Francisco Single-Cell Analysis Center

Chapter 6: Market Breakdown by End User

  • Introduction
  • Cancer Applications
    • Precision Medicine
    • Cancer Biomarker Status
    • Cancer Market Segments
  • Reproductive Health Applications
  • Transplant Diagnostics Applications

Chapter 7: Liquid Biopsy Industry

  • Advanced Sequencing Instruments Industry
  • Droplet Digital PCR Industry
  • Target Enrichment and Amplification Industry
  • Single-Cell DNA Polymerase Industry
  • Non-Invasive Prenatal Testing Industry
  • Fetal Cell NIPT Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Assay Industry

Chapter 8: Industry Acquisitions and Strategic Alliances

  • Acquisitions
  • Strategic Alliances
    • Key Trends
    • 2017 Alliances
    • 2018 Alliances

Chapter 9: Liquid Biopsy Markets

  • Forces Driving Growth
  • Liquid Biopsy Market by Indication
  • Liquid Biopsy Market by Biomarker Type
  • Liquid Biopsy Market by Analysis Platform
  • Liquid Biopsy Market by Analysis Purpose
  • Non-Invasive Prenatal Testing Market
  • Cancer Markets
    • Cancer Market by Indication
    • Cancer Market by Analysis Purpose
    • Cancer Market by Biomarker Class
    • Cancer Market by Analysis Method
    • Breast Cancer Market
    • Colorectal Cancer Market
    • Hematological Cancer Market
    • Lung Cancer Market
    • Pan-cancer Market
  • Transplant Markets
  • Regional Market Analysis

Chapter 10: Patent Review/ New Developments

  • Circulating Tumor Cell Patents
  • Exosome Patents
  • Cell-free DNA Patents
  • Liquid Biopsy and Sequencing-related Patent Issues

Chapter 11: Company Profiles

  • ACCURAGEN, INC.
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • ADVANCED CELL DIAGNOSTICS INC.
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • ALCEDIAG
  • AMOY DIAGNOSTICS CO. LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARCEDI BIOTECH APS
  • ARUP LABORATORIES
  • ASURAGEN INC.
  • ATRECA INC.
  • AVIVA BIOSCIENCES
  • BAYLOR GENETICS
  • BECTON, DICKINSON AND CO.
  • BELLWETHER BIO INC.
  • BERRY GENOMICS CO. LTD.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIOCORE CO. LTD.
  • BIODESIX INC.
  • BIOFLUIDICA INC.
  • BIOGAZELLE
  • BIOMARX INC.
  • BIO-RAD LABORATORIES INC.
  • BIO-TECHNE LTD.
  • BIOVENDOR-LABORATORNI MEDICINA A.S.
  • BLUESTAR GENOMICS INC.
  • BOREAL GENOMICS
  • CANCER GENETICS INC.
  • CAREDX INC.
  • CEGAT GMBH
  • CELLMAX LIFE
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CIRCULOMICS INC.
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • COLOR GENOMICS
  • CS GENETICS LTD.
  • CYGNUS BIOSCIENCES CO. LTD.
  • CYNVENIO BIOSYSTEMS INC.
  • CYTOTRACK APS
  • DATAR CANCER GENETICS LTD.
  • DIACARTA INC.
  • DIAGNOLOGIX LLC
  • DIAGNOMICS
  • DIRECT GENOMICS CO. LTD.
  • DNA ELECTRONICS LTD.
  • DNALYTICS
  • DNANEXUS INC.
  • DOVETAIL GENOMICS LLC
  • ENVISION GENOMICS
  • EPIC SCIENCES INC.
  • EUROFINS SCIENTIFIC
  • EXACT SCIENCES CORP.
  • EXOSOME SCIENCES INC.
  • EXPEDEON AG
  • EZLIFE BIO INC.
  • FABRIC GENOMICS
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • GENAPSYS INC.
  • GENEDX INC.
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENETICS RESEARCH LLC
  • GENOMATIX GMBH
  • GENOMIC HEALTH INC.
  • GENOMONCOLOGY
  • GENOSPACE
  • GENEXOSOME TECHNOLOGIES INC.
  • GIGAGEN INC.
  • GOLDEN HELIX
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HELITEC
  • HELIX OPCO LLC
  • HTG MOLECULAR DIAGNOSTICS INC.
  • ILLUMINA INC.
  • IMMUNOVIA AB
  • INEX INNOVATIONS EXCHANGE PTE. LTD.
  • INIVATA LTD.
  • INTERPACE DIAGNOSTICS LLC
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JBS SCIENCE INC.
  • KONINKLIJKE PHILIPS N.V.
  • LABORATORY CORP. OF AMERICA INC.
  • LEXENT BIO INC.
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • MAMMOTH BIOSCIENCES INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME LABS PVT. LTD.
  • MEDOMICS LLC
  • MENARINI SILICON BIOSYSTEMS SPA
  • MERCK KGAA
  • MOLECULAR HEALTH GMBH
  • MYRIAD GENETICS INC.
  • NAMOCELL INC.
  • NANOSTRING TECHNOLOGIES INC.
  • NANOVIEW BIOSCIENCES INC.
  • NATERA INC.
  • NAVERIS INC.
  • NEOGENOMICS LABORATORIES
  • NEW ENGLAND BIOLABS
  • NEW ONCOLOGY GMBH
  • NIPD GENETICS
  • N-OF-ONE INC.
  • NOVOGENE CO. LTD.
  • NUGEN TECHNOLOGIES INC.
  • NUPROBE INC.
  • NX PRENATAL INC.
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PANGAEA ONCOLOGY
  • PARADIGM DIAGNOSTICS INC.
  • PARSEQ LAB CO. LTD.
  • PATHWAY GENOMICS CORP.
  • PERSONAL GENOME DIAGNOSTICS INC.
  • PIERIANDX
  • PORTABLE GENOMICS LLC
  • PRECIPIO INC.
  • PREDICINE INC.
  • PREMAITHA HEALTH PLC
  • PRENETICS
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANTAPORE INC.
  • QUANTUM BIOSYSTEMS INC.
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECELLS SAS
  • RARECYTE INC.
  • REAL TIME GENOMICS INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SCREENCELL
  • SEEKIN
  • SENGENICS LTD.
  • SEQUENCING.COM
  • SEVEN BRIDGES GENOMICS INC.
  • SINGLERA GENOMICS INC.
  • SOPHIA GENETICS
  • SPERA MEDICAL
  • SPHERE FLUIDICS LTD.
  • STILLA TECHNOLOGIES
  • STRAND LIFE SCIENCES PVT. LTD.
  • STRATOS GENOMICS INC.
  • SYAPSE
  • SYSMEX INOSTICS GMBH
  • TAI DIAGNOSTICS INC.
  • TAKARA BIO INC.
  • THERMO FISHER SCIENTIFIC INC.
  • THORNE DIAGNOSTICS INC.
  • TRANSPLANT GENOMICS
  • TROVAGENE INC.
  • TWINSTRAND BIOSCIENCES
  • TWO PORE GUYS INC.
  • TYMORA ANALYTICAL OPERATIONS LLC
  • UBIQUITY GENOMICS INC.
  • VORTEX BIOSCIENCES
  • XING TECHNOLOGIES LLC
  • VELA DIAGNOSTICS
  • VOLITIONRX
  • VORTEX BIOSCIENCES
  • YIKON GENOMICS CO. LTD.

List of Tables

  • Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2023
    • Table 1: Liquid Biopsy Sample Types
    • Table 2: Liquid Biopsy Report Scope
    • Table 3: Global Liquid Biopsy Market, by Analysis Type, Through 2023
    • Table 4: Forces Driving Growth
    • Table 5: Key Trends in Liquid Biopsy Market
    • Table 6: Liquid Biopsy Industry Subsectors
    • Table 7: Liquid Biopsy Biomarker Classes
    • Table 8: Single-Cell Analysis to Identify Cancer Driver Mutations
    • Table 9: Genomics-based Oncology Workflow
    • Table 10: Unique Challenges of CTC Capture and Analysis
    • Table 11: CTC Workflow
    • Table 12: Cell Differentiators
    • Table 13: Cell Isolation Technologies
    • Table 14: CTC Sample Preparation Technologies
    • Table 15: Single-Cell Analysis Technologies
    • Table 16: Estimated Annual Solid Biopsy Procedures Performed in the United States for Selected Cancers
    • Table 17: Main Risks for Needle-based Tissue Biopsies
    • Table 18: Factors in Tissue Biopsy
    • Table 19: Prenatal Invasive Testing Technologies
    • Table 20: Invasive Versus Non-invasive Prenatal Technologies
    • Table 21: Key Liquid Biopsy Research and Development Programs
    • Table 22: Single-Cell Core Research Facilities
    • Table 23: Source of Foreign Biomarkers for Liquid Biopsy Applications
    • Table 24: Personalized Medicine Driven by Common Cancer Genetic Mutations
    • Table 25: Cancer Liquid Biopsy Biomarker Clinical Status
    • Table 26: Cancer Liquid Biopsy Market Segments
    • Table 27: Reproductive Health Screening Applications
    • Table 28: Ethical Issues Associated with NIPT
    • Table 29: Transplant Diagnostics Applications
    • Table 30: Key Segments and Trends within the Liquid Biopsy Industry
    • Table 31: Advanced Sequencing Industry Company Positioning
    • Table 32: End-to-End Sequencing Approaches
    • Table 33: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 34: Digital PCR Liquid Biopsy Industry
    • Table 35: Target Enrichment Industry
    • Table 36: Single-Cell DNA Polymerase Industry
    • Table 37: NIPT Industry
    • Table 38: Estimated Market Share for NIPT, 2018
    • Table 39: Germany NGS-based Non-invasive Prenatal Diagnostic Companies, 2017
    • Table 40: NIPT Test Licensing, by Country
    • Table 41: Fetal Cell NIPT Industry
    • Table 42: CTC Separations Industry
    • Table 43: Liquid Biopsy Assay Industry: Company Focus
    • Table 44: Example of NGS-based Liquid Biopsy Market Differentiation
    • Table 45: Liquid Biopsy Industry Acquisitions, January 2017-November 2018
    • Table 46: Liquid Biopsy Strategic Alliances, January 2017-November 2018
    • Table 47: Liquid Biopsy Key Forces Driving Growth and Implications, 2023
    • Table 48: Global Liquid Biopsy Market, by Indication, Through 2023
    • Table 49: Global Liquid Biopsy Market, by Biomarker Type, Through 2023
    • Table 50: FDA-Approved or CE-Marked Tests with Epigenetic Component
    • Table 51: Global Liquid Biopsy Market, by Analysis Platform, Through 2023
    • Table 52: Global Liquid Biopsy Market, by Analysis Purpose, Through 2023
    • Table 53: Global NIPT Market, by Analysis Purpose, Through 2023
    • Table 54: Global NIPT Market, by Risk Type, Through 2023
    • Table 55: Global NIPT Market, by Biomarker Class, Through 2023
    • Table 56: Global NIPT Market, by Analysis Method, Through 2023
    • Table 57: Limitations of Solid Biopsy in Cancer Applications
    • Table 58: Low-Frequency Mutation Detection
    • Table 59: Global Liquid Biopsy Cancer Market, by Indication, Through 2023
    • Table 60: Five-year Survival Rate for Ovarian Cancer
    • Table 61: National Institutes of Health Liquid Biopsy Early Detection Initiative
    • Table 62: Molecular Thyroid Nodule Classifier Test Company Positioning
    • Table 63: Global Liquid Biopsy Cancer Market, by Analysis Purpose, Through 2023
    • Table 64: MRI and Liquid Biopsy Methods
    • Table 65: Early Detection Tissue of Origin Approaches
    • Table 66: Global Liquid Biopsy Cancer Market, by Biomarker Class, Through 2023
    • Table 67: Global Liquid Biopsy Cancer Market, by Analysis Method, Through 2023
    • Table 68: Global Breast Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 69: Global Colorectal Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 70: Hematological Cancer Market, by Analysis Method, Through 2023
    • Table 71: Global Lung Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 72: Global Pan-cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 73: Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2023
    • Table 74: Global Liquid Biopsy Transplant Market, by Organ Type, Through 2023
    • Table 75: Transplant Procedures Performed in the United States, 2016 to 30 Sept. 2018
    • Table 76: Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2023
    • Table 77: Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2023
    • Table 78: Global Liquid Biopsy Market, by Region, Through 2023
    • Table 79: Global Cancer Liquid Biopsy Market, by Region, Through 2023
    • Table 80: Global NIPT Liquid Biopsy Market, by Region, Through 2023
    • Table 81: Global Transplant Liquid Biopsy Market, by Region, Through 2023
    • Table 82: Patent Activity for Circulating Tumor Cells (CTCs), by Country/Region, 2008-2018
    • Table 83: Patent Activity for Exosomes, by Country/Region, 2008-2018
    • Table 84: Patent Activity for Cell-free DNA (cfDNA), by Country/Region, 2008-2018
    • Table 85: Status of Liquid Biopsy and Sequencing-related Patent Disputes

List of Figures

  • Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2017-2023
    • Figure 1: How Cancer Genomics Drives Liquid Biopsy